Welcome: Guest | Site Use Options | Register | Login |

Portola Pharmaceuticals files for $150 million IPO

Awardee Story Portola Pharmaceuticals files for $150 million IPO
Date: Apr 15, 2013
Author: Kristin Jones
Source: MarketWatch ( click here to go to the source)

Portola Pharmaceuticals has filed plans to raise up to $150 million through an initial public offering.

The biopharmaceutical company focuses on developing treatments for blood disorders including thrombosis--when a blood clot forms inside a blood vessel. Portola intends to use the proceeds from the IPO to fund its study and development of its lead compound Betrixaban and other drug candidates.

Betrixaban is being developed as a preventive treatment for venous thromboembolism in acutely ill patients.

The company in 2012 reported a profit of $11.4 million, down 43% from the previous year as collaboration and license revenue decreased.

The last two years' profit was largely due to the recognition of deferred revenue after the end of two of the company's collaboration agreements, with Merck & Co. MRK +0.68% and Novartis AG (NVS, NOVN.VX). Portola doesn't yet have any products approved for sale.

The company plans to list on the Nasdaq Global Market under the symbol "PTLA."

News Bureau

Your OPPORTUNITY to upload into this extensively used SBIR-STTR Tracking system

  • Published articles about YOUR SBIR-involved firm
  • Press releases for pick-up by other sources
  • Professional papers; White papers; relevant Business materials

It is a rare issue of the major Business Press - WSJ; New York Times; Washington Post - and regional equivalents; magazines of similar importance - The Economist, Fortune, Forbes etc - and now a wealth of electronic communications and daily news feeds that does not include reference to, or articles about, one/more SBIR-STTR Awardees. With the focus usually on what the firm is about - their technical achievement or business emphasis - it is an unusual coverage that even mentions their SBIR involvement. An integral part of the extensive range of data we continuously assembled in our system on all SBIR-STTR involved firms includes this type of press coverage.  Much that we gather includes firms no longer SBIR involved or still in business, nor now eligible. ...more

Contact information

Innovation Development Institute, LLC

   45 Beach Bluff Avenue, Suite 300
     Swampscott,  MA 01907-1542

  Tel:  (781) 595-2920